University of Miami Leonard M. Miller School of Medicine (UMMSM) - Bascom Palmer Eye Institute
Welcome,         Profile    Billing    Logout  
 3 Trials 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rosa, Potyra
IIH EVOLVE, NCT05347147 / 2021-006664-24: A Trial to Determine the Efficacy and Safety of Presendin in IIH

Terminated
3
14
Europe, US, RoW
Presendin, Placebo
Invex Therapeutics Ltd., Premier Research Group plc, University Hospitals Birmingham Neuro Ophthalmology Reading Centre, Birmingham, UK, Iowa Visual Field Reading Centre, Iowa, USA
Idiopathic Intracranial Hypertension
09/23
10/23
Lam, Byron
IIH EVOLVE, NCT05347147 / 2021-006664-24: A Trial to Determine the Efficacy and Safety of Presendin in IIH

Terminated
3
14
Europe, US, RoW
Presendin, Placebo
Invex Therapeutics Ltd., Premier Research Group plc, University Hospitals Birmingham Neuro Ophthalmology Reading Centre, Birmingham, UK, Iowa Visual Field Reading Centre, Iowa, USA
Idiopathic Intracranial Hypertension
09/23
10/23
liMeliGhT, NCT06388200: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Recruiting
3
150
US
Sub-Retinal Administration of OCU400-301
Ocugen
Retinitis Pigmentosa
06/25
10/26
TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Recruiting
2
140
US
ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo
Alkeus Pharmaceuticals, Inc.
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
12/24
03/25
PRODYGY, NCT05748873: Promising ROd-cone DYstrophy Gene TherapY

Recruiting
1/2
33
Europe, US
SPVN06
SparingVision
Retinitis Pigmentosa
03/25
03/29
LIGHTHOUSE, NCT05878860: ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

Recruiting
1/2
21
US
ATSN-201
Atsena Therapeutics Inc.
X-linked Retinoschisis
10/25
10/29
Platypus, NCT05902962: SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Recruiting
1
20
US
VP-001
PYC Therapeutics
Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
05/24
05/24
NCT06140329: Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Recruiting
N/A
40
Europe, US, RoW
PYC Therapeutics
Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
03/26
06/26
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27

Download Options